10 February 2025

BioJECT™ – drug release testing of injectables

Evaluating subcutaneous injections presents significant challenges due to factors such as shear stress, environmental transitions, and physiological complexity. Robust in-vitro methods are needed to simulate physiological conditions accurately.

BioJECT™ (patent-pending), developed in partnership with the National University of Singapore, is a cutting-edge solution for assessing drug release from subcutaneous (SubQ) injectable products.

Shaping the future of SubQ Testing.
This innovative approach employs a biomatrix that not only mimics SubQ tissue but also simulates tissue resistance while providing a microenvironment to hold and shape in situ implants or other more viscous formulations, such as oily emulsions or suspensions upon injection. Integrated into a flowthrough dissolution cell, BioJECT™ enables biopredictive characterization of the drug release profile, thereby facilitating more effective testing and optimization of subcutaneous delivery systems.

Versatile R&D tool – for insulin research and beyond.
Initially developed to investigate the release and permeation mechanisms of various insulin formulations, BioJECT™ has proven to be a versatile research and development tool. It is not only effective for insulin but also for in-situ forming implants, other peptides, and small molecules. This adaptability makes BioJECT™ a valuable asset in pharmaceutical research.

Unmatched flexibility and precision.
With the CE 7smart, the flow-through dissolution method offers exceptional flexibility in media volumes and ensures consistent testing across a wide range of dosage forms, including injectables. Each flow-through cell can be fitted with an individually prepared biomatrix, making it ideal for screening approaches and allowing users to optimize applications without being restricted to a single administration route.

For more information – get in touch with us!